Hormone therapy for postmenopausal osteoporosis management

References

• White C. Second long term HRT trial stopped early. BMJ. 2002;325(7371):987.
   PubMedGoogle Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel. The NAMS 2017 hormone therapy position statement advisory panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24:728–753.
   PubMedGoogle Scholar
• Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical guidelines committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–839.
   PubMed Web of Science ®Google Scholar
• Jiang X. Hormone therapy for the treatment of postmenopausal osteoporosis: will it soon become a lost art in medicine? Menopause. 2018;25(7):723–727.
   PubMed Web of Science ®Google Scholar
• Caplan L, Hansen KE, Saag KG. Editorial: response to the American College of Physicians osteoporosis guideline, 2017 update. Arthritis Rheumatol. 2017;69(11):2097–2101.
   PubMed Web of Science ®Google Scholar
• Lagari V, Gavcovich T, Levis S. The good and the bad about the 2017 American College of physicians osteoporosis guidelines. Clin Ther. 2018;40(1):168–176.
   PubMed Web of Science ®Google Scholar
• Jiang X, Randhawa SB, Kagan R. Chapter 73 – Estrogen and estrogen analogs for prevention and treatment of osteoporosis. In: Marcus and Feldman’s osteoporosis (5th ed.). Cambridge: Academic Press; 2021. p. 1711–1719.
   Google Scholar
• Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301.
   PubMed Web of Science ®Google Scholar
• Rosen HN. The use of bisphosphonates in postmenopausal women with osteoporosis. UpToDate; [cited 2021 May 4]. Available from: https://www.uptodate.com/contents/postmenopausal-hormone-therapy-in-the-prevention-and-treatment-of-osteoporosis.
   Google Scholar
• Gallagher JC, Tella SH. Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents? Clin Obstet Gynecol. 2013;56(4):749–756.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738.
   PubMed Web of Science ®Google Scholar
• Robbins JA, Aragaki A, Crandall CJ, et al. Women’s Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. Menopause. 2014;21(2):116–123.
   PubMed Web of Science ®Google Scholar
• Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891–2897.
   PubMed Web of Science ®Google Scholar
• Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461–470.
   PubMed Web of Science ®Google Scholar
• Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018;29(5):1049–1055.
   PubMed Web of Science ®Google Scholar
• Richman S, Edusa V, Fadiel A, et al. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause. 2006;13(1):148–155.
   PubMed Web of Science ®Google Scholar
• Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, et al. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol. 1996;88(4 Pt 1):587–592.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104(3):443–451.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher C, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668–2676.
   PubMed Web of Science ®Google Scholar
• Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75(6):1065–1079.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76(1):13–24.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;384:1159–1168.
   Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Where are we 10 years after the Women’s Health Initiative? J Clin Endocrinol Metab. 2013;98(5):1771–1780.
   PubMed Web of Science ®Google Scholar
• Bluming AZ, Tavri C. What are the real risks for breast cancer? Climacteric. 2012;15(2):133–138.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA. 2017;318(10):927–938.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20(3):342–353.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, et al. Brief report: coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2006;21(4):363–366.
   PubMed Web of Science ®Google Scholar
• Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the “timing hypothesis” of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int J Cardiol Heart Vasc. 2019;22:123–131.
   PubMed Web of Science ®Google Scholar
• Kim JE, Chang JH, Jeong MJ, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Sci Rep. 2020;10(1):20631.
   PubMed Web of Science ®Google Scholar
• Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229.
   Google Scholar
• Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257–271.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ, et al. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med. 2008;168(8):861–866.
   PubMedGoogle Scholar
• Gray G, Nelson-Piercy C. Thromboembolic disorders in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012;26(1):53–64.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy; Jackson LM, Parker RM, Mattison DR, editors. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington (DC): National Academies Press (US); 2020. Jul 1. 7, The Safety and Effectiveness of Compounded Bioidentical Hormone Therapy; [cited 2021 July 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562865/
   Google Scholar
• Jiang X, Bossert A, Parthasarathy KN, et al. Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women. Menopause. 2021;28(8):867–874.
   Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–315.
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. 2020;31(12):2271–2286.
   PubMed Web of Science ®Google Scholar
• Lundberg GP, Wenger NK. Menopause hormone therapy: what a cardiologist needs to know – American College of Cardiology; [cited 2021 May 9]. https://www.acc.org/latest-in-cardiology/articles/2019/07/17/11/56/menopause-hormone-therapy.
   Google Scholar
• Crandall CJ, Larson J, Gourlay M, et al. Osteoporosis screening in postmenopausal women 50–64 years-old: Comparison of U.S. Preventive Services Task Force strategy and two traditional strategies in the Women’s Health Initiative. J Bone Miner Res. 2014;29(7):1661–1666.
   PubMed Web of Science ®Google Scholar
• Bansal S, Pecina JL, Merry SP, et al. US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50-64 years. Osteoporos Int. 2015;26(4):1429–1433.
   PubMed Web of Science ®Google Scholar
• Jiang X, Good LE, Spinka R, et al. Osteoporosis screening in postmenopausal women aged 50–64 years: BMI alone compared with current screening tools. Maturitas. 2016;83:59–64.
   PubMed Web of Science ®Google Scholar
• Ghannam S, Blaney H, Gelfond J, et al. The use of FRAX in identifying women less than 65 years needing bone mineral density testing. J Clin Densitom. 2021;24(1):36–43.
   PubMed Web of Science ®Google Scholar
• Lydick E, Cook K, Turpin J, et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 1998;4(1):37–48.
   PubMed Web of Science ®Google Scholar
• Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int. 2001;12(8):699–705.
   PubMed Web of Science ®Google Scholar
• Subramaniam S, Ima-Nirwana S, Chin KY. Performance of Osteoporosis Self-Assessment Tool (OST) in predicting osteoporosis – a review. Int J Environ Res Public Health. 2018;15(7):1445.
   Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Borgstrom F, Jonsson B, et al. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial. Int J Technol Assess Health Care. 2005;21(4):433–441.
   PubMed Web of Science ®Google Scholar
• Lekander I, Borgstrom F, Strom O, et al. Cost-effectiveness of hormone therapy in the United States. J Womens Health. 2009;18(10):1669–1677.
   Web of Science ®Google Scholar
• Lekander I, Borgstrom F, Strom O, et al. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. Menopause Int. 2009;15(1):19–25.
   PubMedGoogle Scholar
• Jiang X, Gruner M, Trémollieres F, et al. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: a systematic review and meta-analysis. Bone. 2017;99:20–25.
   PubMed Web of Science ®Google Scholar
• Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. UpToDate; [cited 2021 May 20]. https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy.
   Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.
   PubMed Web of Science ®Google Scholar
• Greendale GA, Espelan M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med. 2002;162(6):665–672.
   PubMed Web of Science ®Google Scholar
• Papadakis G, Hans D, Gonzalez-Rodriguez E, et al. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal. J Clin Endocrinol Metab. 2016;101(12):5004–5011.
   PubMed Web of Science ®Google Scholar
• Watts NB, Cauley JA, Jackson RD, et al. No increase in fractures after stopping hormone therapy: results from the Women’s Health Initiative. J Clin Endocrinol Metab. 2017;102(1):302–308.
   PubMed Web of Science ®Google Scholar
• Woods GN, Huang M-H, Cawthon PM, et al. Patterns of menopausal hormone therapy use and hyperkyphosis in older women. Menopause. 2018;25(7):738–743.
   PubMed Web of Science ®Google Scholar